PCSK9 Add-On Study Helps Esperion Cover All The Bases With Bempedoic Acid
Executive Summary
Phase II data on use with PCSK9 injectable support bempedoic acid's safety and efficacy profile as an add-on therapy in high cholesterol.
You may also be interested in...
Deaths In Esperion's Long-Term Bempedoic Acid Trial Spur Fears Of Commercial Delay
On top of concerns about safety, which could present regulatory hurdles, bempedoic acid is likely to face a tougher competitive environment after the decline in PCSK9 inhibitor pricing.
PCSK9 Turning Point? Sanofi/Regeneron Dangle Lower Price Carrot For Praluent
ODYSSEY outcomes study homes in on value of PCSK9 inhibition for the subgroup of patients with LDL of at least 100 mg/dL, a potentially large market, but how much will payers ease restrictions in exchange for a lower price?
Esperion's Oral Bempedoic Acid Passes First Phase III Cholesterol Test
'Study 4' results may support a label claim related to reducing inflammation – measured through the high sensitivity C-reactive protein (hsCRP) marker – down the line, the company told investors.